Risk of complications from bone metastases in breast cancer: implications for management

被引:125
|
作者
Plunkett, TA [1 ]
Smith, P [1 ]
Rubens, RD [1 ]
机构
[1] Guys Hosp, Acad Oncol Unit, London SE1 9RT, England
关键词
breast cancer; bone metastases; radiotherapy; bisphosphonates;
D O I
10.1016/S0959-8049(99)00331-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A retrospective analysis of 859 patients who developed bone metastases from breast cancer between 1975 and 1991 was performed in order to identify factors that predict for complications from skeletal disease. The patients were divided into four groups based on the sites of disease at diagnosis of skeletal metastases: bone disease only; bone and soft tissue disease: bone and pleuro-pulmonary disease. bone and liver disease. Patients with metastatic disease confined to the skeleton were most likely to develop a pathological fracture. The time to long bone fracture was similar for all groups, but the least number of such fractures occurred in patients with bone and liver metastases since their survival was shortest (median: 5.5 months; P<0.001). patients with bone metastases only were most likely to require radiotherapy to painful osseous deposits (P = 0.0001) and most rapidly developed spinal cord compression (P = 0.01. data not shown). The results suggest that patients with disease confined to the skeleton at the diagnosis of bone metastases are most likely to develop skeletal-related complications from advanced breast cancer. Such patients may benefit most from treatment with bisphosphonates. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:476 / 482
页数:7
相关论文
共 50 条
  • [41] Radiation therapy in the management of brain metastases from breast cancer
    Tone Fokstuen
    Nils Wilking
    Lars Erik Rutqvist
    Jeanette Wolke
    Anette Liedberg
    Toom Signomklao
    Jan-Olof Fernberg
    Breast Cancer Research and Treatment, 2000, 62 : 211 - 216
  • [42] Prevention of bone metastases from breast cancer by adjuvant bisphosphonate therapy
    Norio Kohno
    Ikuo Kokufu
    Breast Cancer, 2003, 10 (1) : 33 - 37
  • [43] DISODIUM PAMIDRONATE IN THE TREATMENT OF BONE METASTASES FROM BREAST-CANCER
    COLLEONI, M
    BOCHICCHIO, AM
    NOLE, F
    BAJETTA, E
    TUMORI, 1993, 79 (05) : 340 - 342
  • [44] Pharmacotherapy of bone metastases in breast cancer patients
    Petrut, Bianca
    Simmons, Christine
    Broom, Reuben
    Trinkaus, Mateya
    Clemons, Mark
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (06) : 937 - 945
  • [45] Bisphosphonates in Breast Cancer Patients with Bone Metastases
    Diel, Ingo J.
    BREAST CARE, 2010, 5 (05) : 306 - 311
  • [46] Bone metastases in breast cancer
    Allan Lipton
    Current Treatment Options in Oncology, 2003, 4 (2) : 151 - 158
  • [47] Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice
    Li, Bob T.
    Wong, Matthew H.
    Pavlakis, Nick
    JOURNAL OF CLINICAL MEDICINE, 2014, 3 (01) : 1 - 24
  • [48] Treatment options for breast cancer and bone metastases
    Pecherstorfer, Martin
    WOMENS HEALTH, 2009, 5 (02) : 149 - 163
  • [49] Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors
    Brown-Glaberman, Ursa
    Stopeck, Alison T.
    BIOLOGICS-TARGETS & THERAPY, 2012, 6 : 89 - 99
  • [50] Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents
    Patrick, Donald L.
    Cleeland, Charles S.
    von Moos, Roger
    Fallowfield, Lesley
    Wei, Rachel
    Oehrling, Katarina
    Qian, Yi
    SUPPORTIVE CARE IN CANCER, 2015, 23 (04) : 1157 - 1168